Vejiga (irritable)

8-Prenylnaringenin (8-PN) from hops is considered the most potent phytoestrogen yet identified, with higher ERα and ERβ binding affinity than genistein. It has been clinically studied for menopausal symptom relief, with prospective studies showing significant improvement in hot flash-related quality of life.

Alfalfa (Medicago sativa) is a documented dietary source of the phytoestrogen coumestrol and isoflavones including formononetin and biochanin A, which bind estrogen receptors. Estrogenic effects of alfalfa in animals are well-established (infertility in grazing sheep), and it is included among phytoestrogen food sources in authoritative phytoestrogen databases.

A. racemosus contains steroidal saponins (shatavarins) that exhibit phytoestrogenic activity by binding estrogen receptors, modulating FSH and LH levels. Clinical RCTs in perimenopausal women have documented hormone-modulating effects including changes in FSH, LH, and AMH levels. Preclinical studies with A. officinalis root extract showed dose-dependent increases in estrogen and progesterone in female rats.

Epimedium prenylflavonoids, including icariin, act as phytoestrogens by binding to estrogen receptors, exhibiting selective estrogen receptor modulator (SERM)-like properties. Human clinical studies confirm that ICA metabolites appear in serum of postmenopausal women after oral dosing and modulate estrogen-sensitive bone markers. Unlike classical estrogens, Epimedium prenylflavonoids did not activate androgen, glucocorticoid, or progesterone receptors in bioassays.

Biochanin A is an O-methylated isoflavone in red clover that acts as a prodrug, converted by gut bacteria to genistein. It binds ERβ, inhibits aromatase in vitro, and contributes to red clover's overall phytoestrogenic and estrogen-balancing activity in menopausal women.

Black cohosh (Actaea racemosa) is one of the most studied botanicals for menopausal symptoms. It acts primarily through serotonergic and dopaminergic pathways rather than as a classical phytoestrogen. Multiple RCTs and a 2012 meta-analysis support its use for hot flash reduction; however, it does not act through direct estrogen receptor binding in typical clinical use.

A human pilot case study (Skibola 2004, BMC Complementary Medicine, n=3) found bladderwrack intake significantly reduced serum 17β-estradiol and elevated progesterone in pre-menopausal women with abnormal cycles. Menstrual cycle length increased by 5.5–14 days. Findings are preliminary due to very small sample.

Human dietary intervention studies, beginning with the landmark 1987 USDA/Nielsen trial in postmenopausal women, show that boron repletion (3 mg/day) markedly elevates serum 17β-estradiol and testosterone. A 2011 Iranian trial further demonstrated increased free testosterone and reduced pro-inflammatory cytokines after boron supplementation in healthy men. Effects appear most pronounced under low-magnesium conditions.

Broccoli contains glucobrassicin, which is converted to indole-3-carbinol (I3C) and then to diindolylmethane (DIM) in the gut. I3C and DIM shift estrogen metabolism toward the less estrogenic 2-hydroxyestrone pathway. Human studies show that I3C supplementation increases estradiol 2-hydroxylation and alters urinary estrogen metabolite ratios.

Indole-3-carbinol (I3C) and its gut-derived metabolite DIM from Brussels sprouts shift estrogen metabolism toward the less estrogenic 2-hydroxyestrone pathway at the expense of 16α-hydroxyestrone. Human feeding studies and small clinical trials confirm this metabolic shift. This is the basis of interest in cruciferous vegetables for hormone-dependent cancer risk reduction.

Cabbage contains indole-3-carbinol (I3C), which is metabolized to diindolylmethane (DIM) and is a documented inducer of estrogen 2-hydroxylation, shifting estrogen metabolism toward less potent and less carcinogenic metabolites. Human studies demonstrate that I3C intake from cruciferous vegetables significantly increases the 2-hydroxyestrone to 16α-hydroxyestrone ratio.

I3C and DIM from cauliflower modulate estrogen metabolism by promoting 2-hydroxylation over 16α-hydroxylation, and by competing with estrogen at its receptor. Clinical trials confirm these compounds shift the urinary estrone metabolite ratio favorably and reduce estrogen-driven cell proliferation.

Vitex agnus-castus modulates estrogen levels indirectly via pituitary FSH suppression and through direct binding to beta-estrogen receptors. Clinical trials in hyperprolactinemia documented increases in mid-luteal 17β-estradiol alongside raised progesterone after VAC treatment. The herb does not contain estrogens but exhibits weak phytoestrogenic activity through receptor binding.

Chrysin is a flavone from honey and propolis with documented aromatase (CYP19) inhibitory activity in vitro, classified as the most potent aromatase-inhibiting flavone with IC50 of 1.5 µM. By reducing conversion of androgens to estrogens, it is used to modulate estrogen balance; however, human clinical evidence remains primarily in vitro and the bioavailability of oral chrysin is poor.

D-glucarate supports estrogen elimination by inhibiting colonic beta-glucuronidase, the enzyme that deconjugates estrogen glucuronides and allows them to be reabsorbed into circulation. Memorial Sloan Kettering Cancer Center confirms this mechanism increases estrogen elimination and explains its use in estrogen-sensitive breast cancer supportive care. Human clinical evidence remains preliminary.

Daidzein is a soy isoflavone with documented ERβ-preferential binding that acts as a weak phytoestrogen and SERM. It is metabolized by gut bacteria to equol (in ~30–50% of individuals), which has stronger estrogenic activity. Multiple RCTs show soy isoflavones including daidzein provide modest reduction in menopausal vasomotor symptoms.

Daidzin is a phytoestrogen; its metabolite daidzein binds estrogen receptors and acts as a selective estrogen receptor modulator (SERM), preferentially activating ERβ. It can exert both estrogenic and antiestrogenic effects depending on tissue and hormonal context. Human epidemiological and some clinical data support estrogenic modulation.

Damiana contains both aromatase-inhibiting compounds (pinocembrin, acacetin) and phytoestrogenic compounds (apigenin 7-glucoside, Z-echinacin, pinocembrin). In vitro, the methanolic extract showed dose-dependent aromatase inhibition (IC50 63.1 µg/mL). MSKCC notes estrogenic findings are mixed. Evidence is entirely in vitro.

DHEA is the primary precursor for peripheral estrogen synthesis, especially after menopause when ovarian estrogen production declines. DHEA is converted intracellularly to estradiol in peripheral tissues via aromatization, operating as an endocrine buffer for tissue-level estrogen status. Intravaginal DHEA (prasterone) acts locally without significantly raising systemic estrogen levels.

DIM is a cruciferous-vegetable phytonutrient that modulates estrogen metabolism via induction of CYP1A1 and CYP1A2, shifting the 2-OHE1:16α-OHE1 ratio toward the less proliferative 2-hydroxylated pathway. A double-blind RCT (Thomson et al., Cancer Epidemiol Biomarkers Prev, 2017) showed 150 mg DIM twice daily produced a significant, sustained increase in this ratio and raised SHBG in women on tamoxifen. A 2024 large retrospective cohort (n=909 DIM users) confirmed significant alterations across the full urinary estrogen profile in premenopausal women.

Dioscorea contains diosgenin, a phytoestrogenic steroidal sapogenin that stimulates estradiol biosynthesis in animal ovarian cell studies and raised serum estrone and estradiol in a 30-day human dietary trial with post-menopausal women. The human body cannot convert diosgenin to progesterone without laboratory synthesis, limiting its direct hormonal action.

Equol is a non-steroidal estrogen metabolite produced from daidzein by gut bacteria in ~30–50% of Westerners, with higher prevalence in Asian populations. It has higher ERβ affinity than its parent daidzein and has been studied specifically as a SERM for menopausal symptoms and bone turnover. RCTs show equol supplementation improves bone biomarkers in postmenopausal women, including non-producers.

Fennel exerts weak estrogenic activity via its constituent anethole and structurally related polymers (dianethole, photoanethole), which bind estrogen receptors. Animal studies confirm increases in reproductive organ weight and follicle counts; limited human data show modest or non-significant effects on sex hormone levels.

Fenugreek contains phytoestrogens—notably diosgenin and protodioscin—that bind estrogen receptors and raise plasma estradiol. Clinical RCTs in peri- and postmenopausal women report significant increases in circulating estradiol with standardized fenugreek seed extract. These estrogenic effects underlie documented benefits on vasomotor symptoms, mood, and hormonal balance.

Flaxseed is the richest known dietary source of plant lignans, predominantly secoisolariciresinol diglucoside (SDG), which gut bacteria convert to the enterolignans enterolactone and enterodiol—weak phytoestrogens that modulate estrogen metabolism. RCTs show flaxseed increases urinary 2-OHE1 concentration and the 2:16 hydroxyestrone ratio in postmenopausal women, shifting estrogen metabolism toward less genotoxic pathways.

Formononetin is a methoxylated isoflavone found in red clover and licorice that serves as a prodrug, metabolized by gut bacteria to daidzein and subsequently to equol in some individuals. It binds ERβ and functions as a phytoestrogen, contributing to estrogen balance via selective ER modulation.

Genistein is a soy isoflavone that acts as a selective estrogen receptor modulator (SERM) with preferential binding to ERβ, modulating estrogen-dependent tissues. Multiple RCTs have shown 54 mg/day genistein improves bone density and reduces menopausal vasomotor symptoms in postmenopausal women. It also inhibits aromatase and 17β-hydroxysteroid dehydrogenase in vitro, contributing to estrogen metabolism modulation.

A 2017 clinical study found that geranium EO inhalation elevated salivary estrogen levels in women. The oil is classified as phytoestrogenic in traditional Chinese medicine and is used clinically for hormonal regulation. The evidence is preliminary but human-clinical.

Glycitin is the glucoside precursor of glycitein, a phytoestrogen that acts as a selective estrogen receptor modulator (SERM). It binds to both ERα and ERβ receptors, exerting agonistic or antagonistic effects depending on tissue estrogen milieu. This bidirectional estrogenic regulation is a well-documented property of soy isoflavones, including glycitin. The estrogenic effects of glycitin are directly cited in multiple PMC reviews as a primary attributed health function.

HMR is converted by gut microbiota to enterolactone (ENL), a mammalian lignan that acts as a weak phytoestrogen via estrogen receptor alpha and beta. In vitro studies using MCF-7 cells confirm mild ER-dependent estrogenic activity for both HMR and ENL, far weaker than estradiol. A human RCT found that HMR combined with indole-3-carbinol significantly shifted estrogen metabolism toward the more favorable C-2 hydroxylation pathway.

HMRlignan is converted to enterolactone, a SERM that binds estrogen receptors ERα and ERβ with mild estrogenic activity much weaker than endogenous estradiol. Enterolactone also inhibits aromatase (CYP19A1) and 17β-HSD, reducing local estrogen biosynthesis. These dual agonist/antagonist and aromatase-inhibiting mechanisms allow context-dependent modulation of estrogen signaling.

Hops (Humulus lupulus) strobiles contain 8-prenylnaringenin (8-PN), the most potent phytoestrogen yet identified, along with isoxanthohumol and xanthohumol. Clinical studies show hop extracts standardized to 8-PN reduce menopausal hot flashes. European regulatory bodies have reviewed hop-based menopausal health claims.

HMR is a phytoestrogen precursor that gut bacteria convert to enterolactone (ENL), a mammalian lignan with mild estrogen receptor (ER)-mediated activity. In vitro studies confirm ER-dependent proliferative effects in MCF-7 cells that are blocked by tamoxifen. A clinical study in 22 postmenopausal women showed that 36–72 mg/day HMRlignan for 8 weeks significantly raised serum ENL and reduced hot-flash frequency. ENL may also modulate estrogen balance by inhibiting aromatase and raising sex-hormone-binding globulin (SHBG).

Indole-3-Carbinol (I3C) is a glucosinolate breakdown product from cruciferous vegetables that promotes 2-hydroxylation of estrogens via CYP1A induction, reducing the ratio of genotoxic estrogen metabolites. Epidemiological, laboratory, and animal studies support its role as a negative regulator of estrogen-driven cell proliferation. It is the precursor to DIM and is used clinically for estrogen balance and cervical dysplasia.

Isoflavones are plant-derived phytoestrogens (including genistein, daidzein, formononetin, biochanin A) that bind estrogen receptors with ERβ preference, functioning as weak SERMs. Systematic reviews confirm modest efficacy in reducing menopausal hot flash intensity and supporting bone density at ≥50 mg/day. They are the most extensively studied class of estrogen-modulating botanicals.

Kale contains glucobrassicin, which hydrolyzes to indole-3-carbinol (I3C) and then to diindolylmethane (DIM) in the gut. I3C and DIM shift hepatic estrogen metabolism toward the 2-OHE1 ('favorable') pathway and away from the 16α-OHE1 pathway associated with proliferative effects. Epidemiological studies link high cruciferous vegetable intake with lower hormone-dependent cancer risk.

Kudzu (Pueraria lobata) root is a rich source of puerarin, daidzin, and daidzein—isoflavones with documented ERβ binding and phytoestrogenic activity. It has been used in TCM for menopausal symptoms and alcohol dependence. Clinical studies on its isoflavone content and estrogenic metabolites support its classification as a phytoestrogen source for estrogen balance.

Several compounds in licorice root—including glabrene, glabridin, and isoliquiritigenin—exhibit phytoestrogenic activity by binding estrogen receptors. Glycyrrhizin has also been shown to modulate estrogen action. This dual estrogenic/anti-estrogenic profile supports effects on estrogen-dependent conditions including menopause and PMS. Evidence originates from in vitro and clinical studies on menopausal outcomes.

Lignans are polyphenolic compounds found in flaxseed, whole grains, and vegetables that are metabolized by gut microbiota to enterolactone and enterodiol—mammalian phytoestrogens structurally similar to estradiol. They modulate hormonal balance, show potential in alleviating menopausal symptoms, and have been linked to reduced estrogen-dependent cancer risk in prospective cohort studies.

Maca (Lepidium meyenii/peruvianum) is an Andean adaptogen that influences hormone balance via the hypothalamic-pituitary axis rather than direct estrogenic activity. A double-blind crossover RCT (n=34 postmenopausal women) showed Maca-GO stimulated E2 production, suppressed FSH, and alleviated menopausal symptoms. Traditional use as a fertility and vitality herb in Peru dates back centuries.

Phytoestrogens are structurally diverse plant compounds (isoflavones, lignans, coumestans, stilbenes) that bind human estrogen receptors and modulate estrogenic activity. They are used as alternatives to hormone replacement therapy and have documented effects on menopausal symptoms, estrogen metabolism, and hormone-dependent tissue health in multiple clinical trials.

Pregnenolone is the obligate biochemical precursor to all estrogens via the steroidogenic cascade (pregnenolone → DHEA → androstenedione → estrogens). Age-related pregnenolone decline reduces available substrate for estrogen synthesis. Altered pregnenolone metabolism is associated with impaired follicular development and anovulation in women with enzyme deficiencies.

Progesterone acts as the physiological counterbalance to estrogen, downregulating estrogen receptors and opposing estrogen-driven endometrial and breast tissue proliferation. In perimenopause, anovulatory cycles produce estrogen without adequate progesterone, creating relative estrogen excess. This imbalance is implicated in heavy periods, PMS, breast tenderness, and endometrial hyperplasia.

Red clover (Trifolium pratense) contains four phytoestrogenic isoflavones—formononetin, biochanin A, daidzein, and genistein—that bind ERβ and function as tissue-selective SERMs. RCT evidence for hot flash reduction is mixed; some trials show benefit at ≥120 mg isoflavones/day. It is among the most researched phytoestrogen sources for menopausal estrogen balance.

Resveratrol is a stilbene phytoestrogen that binds ERα as a pathway-selective ligand, modulating inflammatory responses without stimulating breast or uterine cell proliferation. It also inhibits aromatase and steroidogenic enzymes, affecting plasma estrogen levels. PMC-published clinical trials show resveratrol plus equol improves bone turnover biomarkers in postmenopausal women.

A randomized double-blind placebo-controlled trial found schisandra extract was effective for menopausal symptoms including hot flushes, sweating, and heart palpitations. A combination product containing schisandra increased urinary 2-OHE concentrations in peri/postmenopausal women, suggesting favorable estrogen metabolism. In TCM, schisandra is used for excess sweating and menopausal complaints.

Secoisolariciresinol diglucoside (SDG) is the principal lignan phytoestrogen in flaxseed, classified as a phytoestrogen that modulates estrogen receptor expression and metabolism. Animal studies show SDG ameliorates estrogen-deficiency-induced osteoporosis via ER modulation; SDG is gut-metabolized to enterolactone and enterodiol, which bind estrogen receptors.

Sesame lignans (sesamin, sesamolin) are converted by intestinal microbiota into enterolactone, a mammalian lignan that weakly binds estrogen receptors and may also stimulate Sex Hormone-Binding Globulin (SHBG) synthesis. A 5-week clinical study in 24 postmenopausal women found that 50 mg sesame powder improved hormone status. These phytoestrogenic properties are documented but modest compared to classical phytoestrogens.

Soy isoflavones function as selective estrogen receptor modulators (SERMs), binding ERα and ERβ with tissue-selective effects. They exert weak estrogenic effects in estrogen-deficient states (e.g., menopause) and may competitively modulate estrogen activity in estrogen-replete states. This dual modulation is well-documented mechanistically and in clinical pharmacology.

Soy isoflavones (primarily genistein and daidzein) are well-documented phytoestrogens that bind estrogen receptors with ERβ preference, modestly reducing menopausal hot flash frequency and intensity. Multiple RCTs and systematic reviews support their use at ≥50 mg/day for menopausal vasomotor symptoms and bone density maintenance.

Soy isoflavones are phytoestrogens that interact with estrogen receptors alpha and beta, acting as selective estrogen receptor modulators with tissue-specific agonist or antagonist activity. When endogenous estrogen is low (e.g., postmenopause), they can exert mild estrogenic agonism; when estrogen is high (e.g., premenopause), they may compete as partial antagonists. By inhibiting aromatase and modulating sex hormone-binding globulin, soy isoflavones can also alter the metabolism and bioavailability of endogenous estrogens.

Sulforaphane is an isothiocyanate from broccoli that modulates estrogen metabolism by inducing phase II detoxification enzymes (NQO1, GST, COMT), reducing DNA-damaging estrogen quinone formation. Animal studies show sulforaphane significantly diminishes mammary tumor formation in E2-exposed rats. Multiple clinical trials are ongoing for cancer prevention including estrogen-dependent tumors.

P. paniculata root consumption significantly elevated plasma estradiol-17β and progesterone in female mice after 30 days (Oshima & Gu, 2003). The plant is noted to have hormonal-like effects, and caution is recommended in estrogen-sensitive conditions. No human clinical trials confirm estrogenic effects.

THIAA's molecular structure is close to a class of ERα antagonists that disrupt coactivator binding via the LxxLL motif. In MCF-7 ERα-positive breast cancer cells, THIAA inhibited estradiol-stimulated proliferation and ERα transcriptional activity. Uniquely, it does not compete directly with estradiol for receptor binding, suggesting a novel coactivator-displacement mechanism.

Vitex agnus-castus (chaste tree berry) modulates the hypothalamic-pituitary axis, inhibiting prolactin and increasing LH, thereby indirectly shifting the estrogen-to-progesterone ratio. Systematic reviews and RCTs demonstrate significant reductions in PMS symptoms; it has been used for gynecological hormone balance in European traditional medicine for over 2,500 years.

Xanthohumol is the principal prenylated chalcone in hops (Humulus lupulus). It is a phytoestrogen that can be metabolized to isoxanthohumol and further to 8-prenylnaringenin (the most potent known phytoestrogen) by gut bacteria. It binds estrogen receptors and modulates estrogen-dependent gene expression in vitro.

In vitro studies have demonstrated estrogenic activity of A. millefolium, attributed to its flavonoid content. This provides a plausible mechanistic basis for its traditional use in female reproductive conditions, though human clinical data specifically on estrogenic endpoints are lacking.

Dong Quai (Angelica sinensis) is used in Traditional Chinese Medicine for thousands of years to regulate female hormones, treat menstrual irregularities, and alleviate menopausal symptoms. Scientific evidence for direct estrogenic activity is conflicting; no estrogenic compounds have been definitively isolated, and clinical RCTs have not confirmed reliable estrogenic effects.

Wild yam (Dioscorea species) contains diosgenin, a steroidal saponin that can be chemically converted to progesterone and DHEA in industrial processes, but the human body cannot perform this conversion. It has been used traditionally in North America and China for female hormonal complaints. Scientific evidence for in vivo hormone balance effects in humans is not well established.